Bio-Techne (NASDAQ:TECH) Announces Quarterly Earnings Results

Bio-Techne (NASDAQ:TECH) released its quarterly earnings results on Wednesday. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.03, FiscalAI reports. The business had revenue of $295.88 million during the quarter, compared to analysts’ expectations of $290.20 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The business’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.42 EPS.

Here are the key takeaways from Bio-Techne’s conference call:

• Bio-Techne reported Q2 revenue of $295.9M (flat YoY) with adjusted EPS up 10% to $0.46 and adjusted operating margin expanded ~100 bps to 31.1%, driven by productivity and cost management.
• Two of the company’s largest cell therapy customers received FDA Fast Track designations, creating a temporary order-timing headwind that cut GMP reagent revenue sharply (cell therapy revenue down >30%) and will depress growth ~300 bps in Q3 before moderating in Q4 and clearing in FY2027.
• Strategic high-growth verticals — cell therapy, proteomic analytical instruments, spatial biology, and precision diagnostics — now represent 47% of revenue (up from 32% in FY2020) and have delivered an upper‑teens CAGR, with strong product momentum (ProteinSimple Leo and ultrasensitive Ella assays, COMET bookings acceleration).
• Geographic strength in Asia continued: China grew mid-single digits for the third consecutive quarter and APAC ex-China grew nearly 20%, reflecting stronger R&D activity from CDMOs, CROs and biotechs.
• Adjusted gross margin declined to 68.5% (from 70.5%) due to unfavorable product/customer mix, but SG&A and R&D discipline helped expand operating margins; cash flow was healthy ($82.4M operating cash) and net leverage remained below 1x EBITDA.

Bio-Techne Stock Up 1.6%

Shares of Bio-Techne stock opened at $66.94 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.81 and a current ratio of 4.54. Bio-Techne has a 52-week low of $46.01 and a 52-week high of $75.69. The company’s 50 day moving average price is $63.25 and its 200-day moving average price is $59.25. The stock has a market capitalization of $10.43 billion, a price-to-earnings ratio of 130.72, a P/E/G ratio of 4.74 and a beta of 1.48.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 27th. Stockholders of record on Monday, February 16th will be issued a $0.08 dividend. The ex-dividend date is Friday, February 13th. This represents a $0.32 annualized dividend and a dividend yield of 0.5%. Bio-Techne’s dividend payout ratio (DPR) is currently 65.31%.

Hedge Funds Weigh In On Bio-Techne

A number of hedge funds have recently modified their holdings of TECH. Wellington Management Group LLP boosted its holdings in shares of Bio-Techne by 349.8% during the third quarter. Wellington Management Group LLP now owns 5,115,133 shares of the biotechnology company’s stock worth $284,555,000 after purchasing an additional 3,978,026 shares during the period. Invesco Ltd. raised its position in Bio-Techne by 7.7% during the 3rd quarter. Invesco Ltd. now owns 3,946,028 shares of the biotechnology company’s stock valued at $219,518,000 after purchasing an additional 283,303 shares during the last quarter. DF Dent & Co. Inc. raised its position in Bio-Techne by 2.1% during the 3rd quarter. DF Dent & Co. Inc. now owns 2,780,961 shares of the biotechnology company’s stock valued at $154,705,000 after purchasing an additional 56,219 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Bio-Techne by 3.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,710,513 shares of the biotechnology company’s stock worth $95,129,000 after buying an additional 49,172 shares during the period. Finally, UBS Group AG grew its position in shares of Bio-Techne by 52.1% in the 3rd quarter. UBS Group AG now owns 1,509,436 shares of the biotechnology company’s stock worth $83,970,000 after buying an additional 517,050 shares during the last quarter. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. UBS Group reaffirmed a “buy” rating and set a $79.00 price target (up previously from $70.00) on shares of Bio-Techne in a research note on Thursday. Robert W. Baird set a $70.00 target price on Bio-Techne in a research report on Thursday. TD Cowen reaffirmed a “buy” rating and issued a $80.00 target price (up previously from $70.00) on shares of Bio-Techne in a research note on Thursday. Wells Fargo & Company lifted their price target on shares of Bio-Techne from $59.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Bio-Techne in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $72.31.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.